STOCK TITAN

Field Trip Health Ltd. to Participate in Citi’s Psychedelic Drug Video Call Series

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced the participation of Co-Founder and CEO Joseph del Moral, along with Chief Scientific Officer Dr. Nathan Bryson, in Citi's Psychedelic Drug Video Call Series.

The event will be hosted by Neena Bitritto-Garg on January 20, 2022, at 10:00 AM Eastern Time. Institutional investors can register through their Citi representative or schedule meetings with management via KCSA Strategic Communications.

Positive
  • None.
Negative
  • None.

TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-Founder and CEO, Joseph del Moral, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in Citi’s Psychedelic Drug Video Call Series.

Hosted by Neena Bitritto-Garg, Vice President Research Analyst, Biotech, the fireside chat with Field Trip will take place on Thursday, January 20, 2022 at 10:00am Eastern Time.

To register for the event, please contact your appropriate Citi representative directly.

Institutional investors interested in scheduling a meeting with Field Trip’s management team, please contact KCSA Strategic Communications at fieldtripIR@kcsa.com.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centres for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth.

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

Cautionary Note Regarding Forward-Looking Information 

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including those set forth in the Company’s Annual Information Form and other market conditions, economic factors, management's ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Investor contacts:
Kathleen Heaney / Tim Regan
KCSA Strategic Communications
fieldtripIR@kcsa.com

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
press@fieldtriphealth.com

SOURCE Field Trip Health Ltd.


FAQ

What is the date and time of the Citi Psychedelic Drug Video Call Series featuring FTRP?

The Citi Psychedelic Drug Video Call Series featuring Field Trip Health Ltd. (FTRP) is scheduled for January 20, 2022, at 10:00 AM Eastern Time.

Who from Field Trip Health Ltd. is participating in the Citi event?

Co-Founder and CEO Joseph del Moral and Chief Scientific Officer Dr. Nathan Bryson will participate in the Citi event.

How can investors register for the Citi Psychedelic Drug Video Call Series?

Investors can register for the Citi Psychedelic Drug Video Call Series by contacting their appropriate Citi representative directly.

How can institutional investors schedule meetings with Field Trip Health Ltd. management?

Institutional investors interested in scheduling meetings with Field Trip Health Ltd. management can contact KCSA Strategic Communications.

FTRP

:FTRP

FTRP Rankings

FTRP Latest News

FTRP Stock Data

9.82M